Compare KRRO & BSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRRO | BSL |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.0M | 169.3M |
| IPO Year | 2019 | N/A |
| Metric | KRRO | BSL |
|---|---|---|
| Price | $13.18 | $13.10 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $34.80 | N/A |
| AVG Volume (30 Days) | ★ 303.9K | 35.4K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.55% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,392,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 181.46 | N/A |
| 52 Week Low | $5.20 | $12.45 |
| 52 Week High | $55.89 | $14.35 |
| Indicator | KRRO | BSL |
|---|---|---|
| Relative Strength Index (RSI) | 51.21 | 65.94 |
| Support Level | $10.32 | $12.83 |
| Resistance Level | $14.78 | $13.33 |
| Average True Range (ATR) | 1.26 | 0.09 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 35.61 | 82.26 |
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The fund also invests in second-lien loans and high yield bonds and employs financial leverage which may increase the risk to the Fund.